| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2121628 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
In this retrospective analysis, pazopanib-induced HTN did not correlate with outcome in pazopanib-treated STS patients. The occurrence of HTN cannot serve as biomarker in this setting.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
F. Duffaud, S. Sleijfer, S. Litière, I. Ray-Coquard, A. Le Cesne, Z. Papai, I. Judson, P. Schöffski, S.P. Chawla, R. Dewji, S. Marreaud, J. Verweij, W.T. van der Graaf,